Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Stalevo opvejer risiciene ved behandling af Parkinsons sygdom ved end- of- dose fluktuationer, der ikke stabiliseres ved behandling med levodopa/ dopa decarboxylasehæmmere.
The Committee for Medicinal Products for Human Use (CHMP) decided that Stalevo’ s benefits are greater than its risks for the treatment of patients with Parkinson’ s disease and end-of-dose motor fluctuations not stabilised on levodopa/ dopa decarboxylase inhibitor treatment.